14-day Premium Trial Subscription Try For FreeTry Free
$1.40
-0.0900 (-6.04%)
At Close: May 07, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $0.0060 $169.56 Tuesday, 7th May 2024 AKBA stock ended at $1.40. This is 6.04% less than the trading day before Monday, 6th May 2024. During the day the stock fluctuated 13.04% from a day low at $1.38 to a day high of $1.56.
90 days $113.65 $133.77
52 weeks $171.20 $133.77

Historical Akebia Therapeutics prices

Date Open High Low Close Volume
Nov 04, 2022 $0.260 $0.280 $0.257 $0.271 1 652 655
Nov 03, 2022 $0.256 $0.320 $0.256 $0.285 3 007 485
Nov 02, 2022 $0.264 $0.280 $0.260 $0.266 737 608
Nov 01, 2022 $0.261 $0.275 $0.256 $0.271 896 089
Oct 31, 2022 $0.268 $0.273 $0.250 $0.255 956 891
Oct 28, 2022 $0.278 $0.287 $0.260 $0.260 1 205 266
Oct 27, 2022 $0.270 $0.283 $0.264 $0.272 1 057 455
Oct 26, 2022 $0.260 $0.278 $0.260 $0.267 986 786
Oct 25, 2022 $0.250 $0.270 $0.250 $0.268 666 141
Oct 24, 2022 $0.265 $0.266 $0.241 $0.253 1 278 240
Oct 21, 2022 $0.271 $0.272 $0.256 $0.260 1 194 437
Oct 20, 2022 $0.276 $0.282 $0.270 $0.271 566 745
Oct 19, 2022 $0.300 $0.305 $0.271 $0.271 2 003 355
Oct 18, 2022 $0.297 $0.310 $0.290 $0.291 831 298
Oct 17, 2022 $0.293 $0.309 $0.284 $0.295 863 752
Oct 14, 2022 $0.295 $0.310 $0.281 $0.289 1 001 920
Oct 13, 2022 $0.280 $0.300 $0.280 $0.287 1 003 651
Oct 12, 2022 $0.290 $0.295 $0.280 $0.285 722 136
Oct 11, 2022 $0.290 $0.315 $0.280 $0.295 1 728 172
Oct 10, 2022 $0.310 $0.313 $0.290 $0.295 1 580 510
Oct 07, 2022 $0.339 $0.342 $0.300 $0.300 1 678 112
Oct 06, 2022 $0.320 $0.360 $0.318 $0.330 1 148 375
Oct 05, 2022 $0.312 $0.328 $0.310 $0.316 1 136 584
Oct 04, 2022 $0.314 $0.333 $0.314 $0.323 903 878
Oct 03, 2022 $0.315 $0.330 $0.310 $0.314 742 896
Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Golden Star

Ticker Date Change Price
BBCA May 03 1.26% $65.44
ADTH May 03 5.56% $3.24
ISTB May 03 0.0425% $47.11
WMT May 03 1.34% $59.82
UNP May 03 0.84% $240.36
INGR May 03 1.75% $114.56
ASH May 03 2.26% $95.85
WU May 03 0.449% $13.37
INVH May 03 1.72% $34.39
INTU May 03 1.89% $629.27
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT